GHX CEO Bruce Johnson introduces a new five-part video series in which he will share insights and observations crowdsourced from one of the largest healthcare communities in the industry. Tune in to celebrate healthcare community triumphs and learn how you can strengthen the healthcare supply chain and minimize financial risk during times of crisis.
Episode 5: Building a Stronger, More Resilient Healthcare Supply Chain
In the final video in the series, Bruce reflects on the impact COVID-19 has had on the healthcare industry, discusses areas that are ripe for evolution and offers suggested next steps.
To the members of the GHX community who are working tirelessly to fight COVID-19:
This is a time of great uncertainty for us all. But we recognize there is even greater pressure on our healthcare providers and suppliers to have answers.
Patients are looking to caregivers to allay the fear their symptoms might be the coronavirus, for definitive diagnosis and a treatment path and how long it will take to fully recover. In turn, providers are looking to manufacturers who can reliably supply the critical medical equipment they desperately need – in the required quantity, in the shortest timeframe possible.
This dynamic ignited GHX to action. We created the COVID-19 Information Center to deliver the insights, data and tools to help our community tackle the pressing challenges of securing supplies, identifying clinically comparable product alternatives and setting up overflow care facilities. Our goal is to empower you to respond to the call for answers.
When GHX was founded 20 years ago there wasn’t a road map, but over time we collectively built an amazing community. This unprecedented time calls on us to re-imagine what healthcare's 'new normal' looks like and we will build a stronger future together.
- Bruce Johnson
Bruce Johnson Video Series (do we have a formal title?)
footer - we can add a button here
To the members of the GHX community who are working tirelessly to fight COVID-19:
This is a time of great uncertainty for us all. But we recognize there is even greater pressure on our healthcare providers and suppliers to have answers.
Patients are looking to caregivers to allay the fear their symptoms might be the coronavirus, for definitive diagnosis and a treatment path and how long it will take to fully recover. In turn, providers are looking to manufacturers who can reliably supply the critical medical equipment they desperately need – in the required quantity, in the shortest timeframe possible.
This dynamic ignited GHX to action. We created the COVID-19 Information Center to deliver the insights, data and tools to help our community tackle the pressing challenges of securing supplies, identifying clinically comparable product alternatives and setting up overflow care facilities. Our goal is to empower you to respond to the call for answers.
When GHX was founded 20 years ago there wasn’t a road map, but over time we collectively built an amazing community. This unprecedented time calls on us to re-imagine what healthcare's 'new normal' looks like and we will build a stronger future together.
This document refers only to areas in Phase II: States and regions with no evidence of a rebound that satisfy the Gating Criteria. In this document CMS recommends:
Optimization of telehealth services, when available and appropriate, continues to be recommended to minimize the need for in-person services. Ensuring that individuals with disabilities have tools for effective communication is a key part of optimizing telehealth services.
All individuals at higher risk for severe COVID-19 illness should continue to shelter in place unless their conditions warrant in-person healthcare. More detailed information about vulnerable and other populations who may need to take precautions is described in the document.
For care that cannot be provided virtually, these recommendations — which are part of a series of phased recommendations — may guide healthcare systems, providers, and facilities as they consider delivering in-person care to non-COVID-19 patients in regions with lower or declining without-rebound, levels of COVID-19.
